First selective aldosterone-blocker now approved for CHF

November 3, 2003

Clinicians will soon be able to offer their patients the first aldosterone-receptor blocker to be approved for the treatment of congestive heart failure (CHF). The FDA recently approved eplerenone (Inspra, Pfizer) to improve the survival of stable patients with left ventricular systolic dysfunction and clinical evidence of CHF following an acute myocardial infarction (MI).

Related Content:

News | Treatment Areas